Published in Medical Letter on the CDC and FDA, December 11th, 2005
The U.S. Centers for Medicare and Medicaid Services have decided not to implement an earlier decision that would have placed all viscosupplement products in the same J-Code for billing next year. As a result of this latest decision, Medicare patients will continue to have access to Synvisc and there will be no change to the method by which product reimbursement in the U.S. is determined for 2006.
Genzyme is dedicated to making a major positive impact on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA